Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual antiplatelet versus batroxobin defibrinogenation therapy in acute large-artery atherosclerotic ischemic stroke
ChiCTR-IPR-15006826Phase 4Recruiting
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Jun 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of clopidogrel, aspirin and batroxobin in ischemic stroke and transient ischaemic attack (TIA) (2 arms), sponsored by General Hospital of the Northern Theater Command. Primary endpoints: Recurrent stroke and Stroke progression and neurological deterioration. Started Jun 2015; status: recruiting.
02
Drugs
clopidogrelaspirinbatroxobin
03
Conditions
ischemic stroketransient ischaemic attack (TIA)
Beyond the preview
Go deeper on ChiCTR-IPR-15006826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006826.